SCNX Key Statistics, Chart & Performance
The current stock price of SCNX is 0.51 USD. In the past month the price decreased by -12.04%. In the past year, price decreased by -88.3%.
SCNX Technical Analysis
SCNX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SCNX. Both the profitability and financial health of SCNX have multiple concerns.
SCNX Financial Highlights
Over the last trailing twelve months SCNX reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS decreased by -283.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.61% | ||
| ROE | -24.86% | ||
| Debt/Equity | 0.01 |
SCNX Forecast & Estimates
SCNX Ownership
About SCNX
Company Profile
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Company Info
SCIENTURE HOLDINGS INC
20 Austin Blvd.
Commack NEW YORK US
Employees: 14
Phone: 18002610281
SCIENTURE HOLDINGS INC / SCNX FAQ
What does SCIENTURE HOLDINGS INC do?
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
What is the current price of SCNX stock?
The current stock price of SCNX is 0.51 USD.
Does SCIENTURE HOLDINGS INC pay dividends?
SCNX does not pay a dividend.
What is the ChartMill rating of SCIENTURE HOLDINGS INC stock?
SCNX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy SCNX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SCNX.
Can you provide the market cap for SCIENTURE HOLDINGS INC?
SCIENTURE HOLDINGS INC (SCNX) has a market capitalization of 20.72M USD. This makes SCNX a Nano Cap stock.
What is the next earnings date for SCNX stock?
SCIENTURE HOLDINGS INC (SCNX) will report earnings on 2026-03-24.